FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martijn Lolkema

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Physiology

Anatomy

Cell Line

Genes & Molecular Sequences

Alleles

Co-author Network

Publications

TOP 3
Michael Jacobetz; Ping Jiang; Duncan I Jodrell; Anne Kultti; Martijn Lolkema; Daniel C Maneval; Tomoaki Nakagawa; Albrecht Neesse; H M Shepard; Jeremy N Skepper; Curtis B Thompson; Tashinga E Bapiro; Meredith E Caldwell; Derek S Chan; Natalie Cook; Christine Feig; Kristopher K Frese; Gregory I Frost; Heather I Zecchini; David A Tuveson
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Kristopher K Frese; Duncan I Jodrell; Martijn Lolkema; Albrecht Neesse; Tashinga E Bapiro; Natalie Cook; David A Tuveson
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Roy J J Verhage; Martijn Lolkema; Sylvia van der Horst; Pieter C van der Sluis; Richard van Hillegersberg
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martijn Lolkema (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Michael Jacobetz; Ping Jiang; Duncan I Jodrell; Anne Kultti; Martijn Lolkema; Daniel C Maneval; Tomoaki Nakagawa; Albrecht Neesse; H M Shepard; Jeremy N Skepper; Curtis B Thompson; Tashinga E Bapiro; Meredith E Caldwell; Derek S Chan; Natalie Cook; Christine Feig; Kristopher K Frese; Gregory I Frost; Heather I Zecchini; David A Tuveson
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Gut 2013;62(1):112-20.
2012: Kristopher K Frese; Duncan I Jodrell; Martijn Lolkema; Albrecht Neesse; Tashinga E Bapiro; Natalie Cook; David A Tuveson
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Cancer discovery 2012;2(3):260-9.
2012: Roy J J Verhage; Martijn Lolkema; Sylvia van der Horst; Pieter C van der Sluis; Richard van Hillegersberg
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Annals of surgical oncology 2012;19(2):684-92.
2012: Pieter C van der Sluis; Maarten S van Leeuwen; Roy J J Verhage; Frank P Vleggaar; Emile E Voest; Marc G H Besselink; Leonie Haverkamp; Hans C A Joore; Hendrik Koffijberg; Christiaan C Kroese; Martijn Lolkema; Margriet J D Prins; Onne Reerink; Inne H M Borel Rinkes; Jelle P Ruurda; Marguerite E I Schipper; Carlo Schippers; Peter D Siersema; Elles Steenhagen; Fiebo Jw Ten Kate; Sylvia van der Horst; Richard van Hillegersberg
Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial).
Trials 2012;13():230.
2012: Rebecca J Brais; Sian Chilcott; Natalie Cook; Pippa G Corrie; Walter C Darbonne; Susan E Davies; Frederic J de Sauvage; Emmanuel Huguet; Asif Jah; Neville V Jamieson; Duncan I Jodrell; Michelle Lockley; Martijn Lolkema; Albrecht Neesse; Maria O'Donovan; Raaj K Praseedom; Ben W Simpson; David A Tuveson; Nicholas R Carroll
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2012;12(1):8-15.
2011: M H G Langenberg; B Loembé; Martijn Lolkema; M Mergui-Roelvink; A Nol-Boekel; J Roodhart; J H M Schellens; Hendrik Verheul; E Brendel; O Christensen; J Krätzschmar; Petronella O Witteveen; Emile E Voest
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(11):2508-15.
2011: Albrecht Neesse; Patrick Michl; Kristopher K Frese; Christine Feig; Natalie Cook; Mike A Jacobetz; Martijn Lolkema; Malte Buchholz; Kenneth P Olive; Thomas M Gress; David A Tuveson
Stromal biology and therapy in pancreatic cancer.
Gut 2011;60(6):861-8.
2011: Maudy Walraven; Petronella O Witteveen; Martijn Lolkema; R van Hillegersberg; Emile E Voest; Hendrik Verheul
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Angiogenesis 2011;14(2):135-41.
2011: Martijn Lolkema; Hendrik-Tobias Arkenau; Kevin Harrington; Patricia Roxburgh; Rosemary Morrison; Victoria Roulstone; Katie Twigger; Matt Coffey; Karl Mettinger; George Gill; T R Jeffry Evans; Johann S de Bono
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(3):581-8.
2011: David Boss; Petronella O Witteveen; J van der Sar; Martijn Lolkema; Emile E Voest; P K Stockman; O Ataman; D Wilson; S Das; J H M Schellens
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(2):431-7.
2010: Morgan Nordstrom-O'Brien; Rob B van der Luijt; Ellen van Rooijen; Ans M W van den Ouweland; Danielle F Majoor-Krakauer; Martijn Lolkema; Aram van Brussel; Emile E Voest; Rachel H Giles
Genetic analysis of von Hippel-Lindau disease.
Human mutation 2010;31(5):521-37.
2010: Jeanine M Roodhart; Marlies H Langenberg; Joost S Vermaat; Martijn Lolkema; Arnold Baars; Rachel H Giles; Els O Witteveen; Emile E Voest
Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patients.
Neoplasia (New York, N.Y.) 2010;12(1):87-94.
2008: Dorus A Mans; Martijn Lolkema; Moniek van Beest; Laura G Daenen; Emile E Voest; Rachel H Giles
Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2.
Experimental cell research 2008;314(6):1229-36.
2008: Martijn Lolkema; Dorus A Mans; Laurien H Ulfman; Stefano Volpi; Emile E Voest; Rachel H Giles
Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor.
European journal of human genetics : EJHG 2008;16(1):73-8.
2007: Martijn Lolkema; Dorus A Mans; Cristel M J T Snijckers; Mascha van Noort; Moniek van Beest; Emile E Voest; Rachel H Giles
The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2.
FEBS letters 2007;581(24):4571-6.
2007: Hendrik Verheul; Martijn Lolkema; Zheng (David) Qian; Yvonne H A Hilkes; Eleni Liapi; Jan-Willem N Akkerman; Roberto Pili; Emile E Voest
Platelets take up the monoclonal antibody bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5341-7.
2006: Rachel H Giles; Martijn Lolkema; Cristel M J T Snijckers; M Belderbos; Petra van Der Groep; Dorus A Mans; Moniek van Beest; Mascha van Noort; roel goldschmeding; Paulus van Diest; Hans Clevers; Emile E Voest
Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis.
Oncogene 2006;25(21):3065-70.
2005: Martijn Lolkema; Michelle L Gervais; Cristel M J T Snijckers; Richard P Hill; Rachel H Giles; Emile E Voest; Michael Ohh
Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain.
The Journal of biological chemistry 2005;280(23):22205-11.
2004: Martijn Lolkema; Niven Mehra; Anita S Jorna; Moniek van Beest; Rachel H Giles; Emile E Voest
The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery.
Experimental cell research 2004;301(2):139-46.
2004: Hans A R Bluyssen; Martijn Lolkema; Moniek van Beest; Michelle Boone; Cristel M J T Snijckers; Maartje Los; Martijn F B G Gebbink; Branko Braam; Frank C P Holstege; Rachel H Giles; Emile E Voest
Fibronectin is a hypoxia-independent target of the tumor suppressor VHL.
FEBS letters 2004;556(1-3):137-42.
2000: M G Kim; G Lee; S K Lee; Martijn Lolkema; J Yim; S H Hong; R H Schwartz
Epithelial cell-specific laminin 5 is required for survival of early thymocytes.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(1):192-201.
1999: S Gallucci; Martijn Lolkema; Polly Matzinger
Natural adjuvants: endogenous activators of dendritic cells.
Nature medicine 1999;5(11):1249-55.